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Abstract
Background: We assessed and compared image quality obtained with clinical 18F-FDG
whole-body oncologic PET protocols used in three different, state-of-the-art digital PET/
CT and two conventional PMT-based PET/CT devices.
Our goal was to evaluate an improved trade-off between administered activity
(patient dose exposure/signal-to-noise ratio) and acquisition time (patient comfort)
while preserving diagnostic information achievable with the recently introduced
digital detector technology compared to previous analogue PET technology.
Methods: We performed list-mode (LM) PET acquisitions using a NEMA/IEC NU2
phantom, with activity concentrations of 5 kBq/mL and 25 kBq/mL for the background (9.5
L) and sphere inserts, respectively. For each device, reconstructions were obtained varying
the image statistics (10, 30, 60, 90, 120, 180, and 300 s from LM data) and the number of
iterations (range 1 to 10) in addition to the employed local clinical protocol setup. We
measured for each reconstructed dataset: the quantitative cross-calibration, the image noise
on the uniform background assessed by the coefficient of variation (COV), and the recovery
coefficients (RCs) evaluated in the hot spheres. Additionally, we compared the characteristic
time-activity-product (TAP) that is the product of scan time per bed position × mass-activity
administered (in min·MBq/kg) across datasets.
Results: Good system cross-calibration was obtained for all tested datasets with
< 6% deviation from the expected value was observed. For all clinical protocol
settings, image noise was compatible with clinical interpretation (COV < 15%).
Digital PET showed an improved background signal-to-noise ratio as compared
to conventional PMT-based PET. RCs were comparable between digital and PMT-
based PET datasets. Compared to PMT-based PET, digital systems provided
comparable image quality with lower TAP (from ~ 40% less and up to 70% less).
Conclusions: This study compared the achievable clinical image quality in three
state-of-the-art digital PET/CT devices (from different vendors) as well as in two
conventional PMT-based PET. Reported results show that a comparable image
quality is achievable with a TAP reduction of ~ 40% in digital PET. This could
lead to a significant reduction of the administered mass-activity and/or scan
time with direct benefits in terms of dose exposure and patient comfort.
Keywords: Digital PET/CT, Image quality, Dose reduction, Protocol optimization
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Background
Positron emission tomography (PET) coupled with computed tomography (CT) is an estab-
lished quantitative imaging technique playing a key role in clinical oncology [1, 2]. In particu-
lar, quantitative or semi-quantitative 18F-FDG-PET/CT examinations cover a large part of
PET indications, such as oncological, cardiac, and neurological imaging [3–5].
To guide clinical protocol validation and optimization, reference methodologies make
use of phantoms with known geometry and activity preparation, representing a reason-
able approximation of patient morphology and activity distribution [6]. To reproduce
patient-relevant conditions, and to assess the signal recovery in small structures, the
National Electrical Manufacturers Association (NEMA)/ International Electrotechnical
Commission (IEC) NU2 phantom is currently a standard reference [7]. Phantoms with
even more anthropomorphic shape also exist but they have not been widely tested so
far and lack in standardization [8].
In the last decade, the clinical introduction of time of flight (TOF) technology and
the point spread function (PSF) correction have substantially enhanced the achievable
image quality [9–12].
In high-end commercial PET/CT devices, conventional analogue photomultipliers
(PM) are replaced by the solid-state technology aiming to improve time resolution,
event collection (consequently improving system sensitivity), localization, and counting
efficiency [13].
In this evolving scenario, standardization and harmonization of 18F-FDG-PET proto-
cols are essential to promote inter-machine and multi-center PET studies. Accordingly,
image protocols have been proposed to satisfy the European Association of Nuclear
Medicine (EANM)/Research 4 Life (EARL) recommendations [14, 15]. However,
present EANM/EARL recommendations were derived for analogue PET systems and
will undoubtedly be updated in the future to account for performances available in
digital PET [16].
To the best of our knowledge, the image quality obtained with the three recently
available commercial digital PET/CT devices using clinical whole-body oncologic 18F-
FDG protocols have not been measured, characterized and compared yet in a single
publication. Furthermore, the clinical image quality obtained with digital PET devices
has not been extensively compared with analogue PET devices in a controlled and stan-
dardized approach.
Our aim was to present, characterize, and compare clinical implementation of 18F-
FDG oncologic PET protocols across different PET technologies (digital vs. analogue).
Accordingly, we performed NEMA/IEC NU2 phantom acquisitions on three recently
installed digital TOF PET/CT systems (three different vendors) and compared the ob-
tained results with the measurement performed in two analogue TOF PET/CT.
In addition, we also compared the signal recovery obtained in hot sphere inserts of
the NEMA/IEC NU2 phantom with present EAMN/EARL recommendations [17].
Methods
Phantom experiment design
The NEMA/IEC NU2 phantom (PTW, Freiburg, Germany) was used to characterize
image quality and quantitative signal recovery in oncologic 18F-FDG-PET/CT images
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from three different digital PET/CT models: GE Healthcare Discovery-MI (GE Health-
care, Waukesha, USA) [13], Philips Vereos (Philips Medical Systems, Cleveland, USA)
[18], and Siemens Biograph Vision 600 (Siemens Healthineers, Knoxville, USA) [19]
and two analogue PET/CT devices: GE Healthcare Discovery 690 [20] and Siemens
Biograph mCT [21].
The phantom's main volume (background) of 9.5 L mimics the human abdominal
shape. It includes six spherical inserts with diameters of: 10, 13, 17, 22, 18, and 37mm,
respectively, and a lung insert (5-mm diameter and 16-cm long cylinder filled with plas-
tic material mimiking the lung density of 0.3 g/mL) positioned in the center of the
phantom to reproduce lung tissue attenuation.
The phantom was filled with a background activity concentration of 5 kBq/mL and
an activity concentration five times higher (25 kBq/mL) in the spherical inserts. The
background activity concentration reproduced the average hepatic activity concentra-
tion measured in patients occurring 18F-FDG oncologic PET 1 h after administration of
a mass-activity of 3.5MBq/kg, corresponding to the recommended dose reference level
in Switzerland at the time of this study for this specific examination [22]. For each
phantom experiment, on each tested PET/CT device, the net background activity con-
centration at the time of the image acquisition start was calculated from the net total
activity injected in the known background volume.
Clinical acquisition/reconstruction parameters
We performed step-and-shoot, single-bed, 300 s long list-mode (LM) PET acquisitions
of the phantom in five PET centers in Switzerland. The phantom was placed on the
PET bed with the equatorial plane of the spherical inserts at the center of the device
field-of-view where the system sensitivity is expected to be maximal.
The LM data were reconstructed according to the local clinical protocol used for
whole-body oncologic 18F-FDG PET examinations reported in Table 1.
To investigate the influence of the image statistics, additional reconstructions were
performed using time subsets of 10, 30, 60, 120, and 180 s obtained from the original
300 s long LM data.
Supplementary reconstructions were performed by varying the number of iterations
from 1 to 10 to characterize the evolution of the signal recovery in background and
spheres. Pertinent image corrections (normalization, dead time, activity decay, random
coincidence, attenuation, and scatter corrections) were applied.
Some clinical reconstruction protocols do not use image smoothing. Therefore, to aid
the comparison of image quality across tested devices, when applicable, image recon-
struction without smoothing was also performed.
All devices used ordered subset expectation maximization (OSEM) based iterative re-
construction algorithm based on an iterations × subsets setup. Additionally, Discovery-
MI’s data was also reconstructed with the Q.Clear algorithm [23] to correctly represent
the local clinical practice. The Q.Clear reconstruction algorithm is a block sequential
regularized EM algorithm with a single relaxation parameter and is not directly com-
parable with other algorithms in terms of the number of iterative updates.
In this study, we used the time (min) ×mass activity (MBq/kg) product (TAP) as a
metric for protocol characterization.
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Table 1 also reports the TAP characteristic of each PET protocol tested. This param-
eter reflects the emission signal available for a given PET acquisition resulting from the
product of the scan duration and the specific injected activity, two key parameters de-
fining a clinical implementation of a PET procedure.
It is worth noting that different image matrices, different field of view (FOV) sizes,
and therefore different pixel sizes were used across tested image protocols and PET
devices.
Background characterization
The PET-to-local dose calibrator cross-calibration (BGcal) was tested by calculating the
ratio between the measured ðAc;bgÞand expected average activity concentration (Ac,bg)




Ac;bg was the average activity concentration obtained by averaging the signal from the
voxels contained in four cubic regions of interest (side of 40 mm) placed in the homo-
geneous background region surrounding the spheres. We consider as acceptable a devi-
ation of < 0.1 from the ideal BGcal = 1. The coefficient of variation (COV) used for
Table 1 Systems, acquisition and reconstruction parameters applied in clinical whole-body












Axial ring extent (mm) 164 261 221 250 153
Energy window (keV) 450–613 435–585 435–650 425–650 425–650
TOF’s resolution (ps) 316 215 540 370 544.3
NEMA System sensitivity
(kcps/MBq)
5.6 16.4 9.6 22 7.5
Acquistion parameters
Acq. Time (min) 1.5 2 2.5 2.5 1.5
Admin. Activity (MBq/kg) 2 2 5 1.5 3.5
Acq. Time (min) × A admin.
(TAP in min ×MBq/kg)
3 4 12.5 3.75 5.25
Reconstruction parameters












(3,15)/(2,10) (4,5) (3,21) (3,16) (3,16)
Filtre Gauss FWHM (mm) 0 0 3 6,4 5
Matrix size 144 × 144/
288 × 288
440 × 440 512 × 512 256 × 256 256 × 256
Pixel size (mm) 4 × 4/2 × 2 1.65 × 1.65 1.59 × 1.59 2.73 × 2.73 2.73 × 2.73
Slice thickness (mm) 4/2 2 5 2.79 3.27
aIn addition to OSEM, clinic FDG PET protocol for the GE Discovery MI also make use of the Q.Clear reconstruction
algorithm (Q-param = 400)
dDigital PET systems
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image noise assessment was defined by the ratio between the standard deviation (SDbg)





The background signal-to-noise ratio (SNR) is the reciprocal of the COV.
We considered a COV ≤ 15% (background SNR ≥ 6.7) as an acceptable noise level for
clinical image interpretation as suggested in the EARL procedure [24]; even if this value
is somehow arbitrary, it has already been used as a reference value in previously pub-
lished works [14, 25, 26], which enables a term of comparison for 18F-FDG PET image
quality assessments. COV as a function of TAP was assessed to investigate possible
margins of optimization in terms of administered activity and/or scan time duration.
The COV for different values of TAP obtained by phantom experiments and TAP
values for a COV = 15% were calculated by linear interpolation between neighboring
measured values.
PET protocol setups were characterized by their specific TAP value. In particular, we
reported and compared TAP obtained with clinical setup (TAPclinic) and TAP obtained
for a matched image noise level by considering a COV = 15% (TAPCOV-15).
Spheres characterization
A cubic volume of interest (VOI), side of 50 mm, was centered on each spherical insert
(j = 1,..,6) of the NEMA/IEC NU2 phantom. Maximum and background-adapted recov-
ery coefficients (RC) were obtained as follows:






where Ac,sph is the expected activity concentration in the spheres, ac,sph,j,max is the mea-
sured maximum voxel value (in Bq/mL) for a given spherical insert. ac,sph,j,A50 is the
average voxel value in each hot insert VOI defined by a 3D iso-contour adapted for
background as defined in [27] and recommended by the EANM Guidelines for FDG
tumor PET imaging [28]. RCs were compared with reference values provided by the
EANM/EARL accreditation protocol [17]. We tested the robustness RCmax and RCA50
as a function of time per bed position by comparing the measured values to the refer-
ence value obtained for the 300 s long acquisition.
Additional spherical VOIs, matching the actual insert volume, were segmented on




Convergence of signal recovery in spheres (j = 1,…,6) as a function of the number of
iterative updates (UPD = iteration × subsets) was studied using the normalized value of
RCmean:
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RC j;mean;N ðUPDÞ ¼
RC j;meanðUPDÞ
maxUPDðRC j;meanÞ
where maxUPD (RCj,mean) is the maximum RCmean value obtained for a given sphere (j)
across the tested number of updates.
Image segmentation on PET data was performed using the PMOD (release 3.903)
software (PMOD Technologies Ltd., Zurich, Switzerland).
Transaxial views across the equatorial plane of spherical inserts of the NEMA/IEC
phantom, obtained for the tested clinical setups, are reported.
Results
Phantom experiment preparation
Parameters describing the experimental phantom preparation at the start of the PET
acquisitions across the five tested PET devices are listed in Table 2.
Background characterization
The system cross-calibration (BGcal) as a function of the acquired statistics (by varying
the time per bed position at matched total activity in the phantom) and the number of
iterations used in the iterative reconstruction process, for the tested acquisition and re-
construction setups, is shown in Fig. 1.
The average BGcal± SD obtained across tested clinical protocol setups for the clinically used
range of iterations (2 to 4 iterations) was BGcal,2–4it= 0.992 ± 0.019 (range 0.963–1.023).
Measured COV values are reported in Fig. 2. The dashed black line indicates a 15%
COV level (SNR = 6.7) used as an upper threshold defining an acceptable level of noise
for clinical image interpretation. All tested clinical PET setups (Table 1) are character-
ized by a COV ≤ 15%.
Figure 3 shows COV as a function of the TAP parameter. All clinical tested setups
were characterized by a COV close to 15%. COV values corresponding to local clinical
TAP and TAP values for a COV = 15% (TAPCOV-15) are reported in Table 3.
Among the tested PET FDG protocols, two different image matrix sizes were used
clinically with the Philips Vereos: 144 × 144 and 288 × 288, respectively. The TOF list-
mode reconstruction [29, 30] leading to the thinner image discretization was character-
ized by a higher noise level: COV = 19% vs. 13.2% (clinical TAP of 3 min ×MBq/kg).
For a given device and same acquisition setups, lower COV levels were obtained using
Gaussian image smoothing compared to not. Across clinical protocol setups, only the
Vereos with the 288 × 288 image matrix had a clinical TAP lower than the TAP value
corresponding to a 15% COV level (3min ×MBq/kg vs. 4.5 min ×MBq/kg). The averaged
Table 2 Average, standard deviation, and minimum and maximum values of activity concentrations
present in the spherical inserts and main phantom background at the PET acquisition time start. The
resulting sphere-to-background activity concentration ratio is also reported
Ac,sph (kBq/mL) Ac,bg (kBq/mL) Sphere-to-bg ratio
Average (n = 5) 25.28 5.06 5.00
Standard deviation (SD) 1.25 0.27 0.27
Min 23.42 4.67 4.63
Max 26.45 5.29 5.46
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TAP value corresponding to a 15% COV calculated across the clinical setups used in
digital PET devices was 40% lower than the respective value calculated for the analogue
PET (2.95min ×MBq/kg, range [1.4–4.5] vs. 5.2 min ×MBq/kg, range [3.7–13.2]).
Signal recovery in spheres
Figure 4 shows RCmax and RCA50 values as a function of increasing sphere size for the
PET setups tested using clinical reconstruction parameters (iterations × subsets and ac-
quisition time) regardless of the image smoothing.
The convergence of the signal recovery in spheres of different sizes obtained as a func-
tion of the number of iterative updates is shown in Additional file 1: Figures S1 and S2.
As reported in Table 4, the normalized value of the RCmean for a sphere of 10 mm
(smaller size) and 17mm (medium size) in diameter are respectively at least 89% and
95% of the maximum RCmean values for the number of iterative updates used in clinical
reconstruction setups. An improved convergence was measured for larger spheres.
The robustness of RCmax and RCA50 according to the PET scan length was assessed
for decreasing scan times (Additional file 1: Figure S2). Tested setups showed RCs to
be stable (less than 15% variation compared to the reference value obtained for the
300-s bed acquisition scan time) for time per bed position ≥ 60 s.
Transaxial views across the equatorial plane of the spherical inserts of the NEMA/
IEC phantom, obtained for the tested clinical setups, are displayed in Fig. 5.
Discussion
This study was the result of a collaboration among five PET centers in Switzerland. Data
were collected from five different PET/CT devices: three recently installed (2017–2018)
Fig. 1 BGcal as a function of the number of iterations used in the iterative reconstruction setups without Gaussian
smoothing (a) and comparison of Gaussian vs. non-Gaussian setups (c) for devices that used the Gaussian smoothing
in the clinic. Similarly, we reported BGcal as a function of the time per bed position (b and d). Digital devices were
labeled with full lines; dashed lines represent obtained results with analogue devices
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digital PET/CT and two analogue PET/CT installed in 2011 (GE Discovery 690) and 2010
(Siemens Biograph mCT), respectively. To the best of our knowledge, this is the first study
comparing image quality from the three currently-available digital PET with those of the
previous analogue generation. Although, absolute system performances have been com-
pared elsewhere in the literature [19], the use of different acquisition and reconstruction
parameters (ex. image matrix and pixel size, number of iterative updates), and the use of
vendor-specific reconstruction algorithms make it difficult to disentangle the specific con-
tribution of each parameters to the final image quality.
This study aimed to investigate and characterize the image quality of clinical whole-
body oncologic 18F-FDG protocols. All tested setups included TOF information and
Fig. 2 COV as a function of the number of iterations used in the iterative reconstruction setups without
Gaussian smoothing (a) and comparison of Gaussian vs. non-Gaussian setups for devices that used the
Gaussian smoothing in the clinic (c). Similarly, we reported the COV as a function of the time per bed
position (b and d). Digital devices were labeled with full lines and dashed lines represent the obtained
results with analogue devices
Fig. 3 COV as a function of the time-activity-product (TAP) for all tested clinical setups. Iterative
reconstruction setups without Gaussian smoothing (a) and comparison of Gaussian vs. non-Gaussian setups
for devices that used the Gaussian smoothing in the clinic (b). Digital devices were labeled with full lines
and dashed lines represent the obtained results with analogue devices
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PSF correction. The direct comparison of the detector technology was beyond the
scope of this work.
Improved TOF capabilities and system sensitivity have been measured and reported
in recent publications [13, 19, 31]. In particular, the gain in system sensitivity resulted
from the interplay of the new digital technology coupled with the adoption of an im-
proved axial extension of the PET detector by some of the available models.
We based our study on PET acquisitions and reconstruction of a NEMA/IEC NU2
body phantom, which is a standard in PET image quality assessments. The phantom
Table 3 Clinical TAP (TAPclinic), COV values obtained for clinical TAP values, characteristic of tested
18F-FDG PET procedures, and TAP computed for a 15% COV level (TAPCOV-15). Reconstruction
protocol setups used in the clinic are labeled with (c)
PET device/recon. procedure TAPclinic
(min ×MBq/kg)
COV (%) at clinical TAP TAPCOV-15
(min ×MBq/kg)
Discovery MI M256 FWHM= 6.4 mm (c) 3.75 8.6 1.4
Discovery MI M256 FWHM= 0mm 3.75 15.2 3.9
Discovery Q.Clear (Q = 400) M256 (c) 3.75 11.4 2.4
Vereos M144 FWHM= 0mm (c) 3 13.2 2.4
Vereos M288 FWHM= 0mm (c) 3 19 4.5
Vision M440 FWHM= 0mm (c) 4 14.1 3.5
Discovery 690 M256 FWHM= 5mm (c) 5.25 12.2 3.7
Discovery 690 M256 FWHM= 0mm 5.25 22 13.2
mCT M512 FWHM= 3mm (c) 12.5 11.5 6.7
mCT M512 FWHM= 0mm 12.5 14.4 11.2
Fig. 4 RCA50 and RCmax values as a function of the sphere diameter for acquisitions performed with a fixed
scan duration of 180 s per bed position. Iterative reconstruction setups without Gaussian smoothing (a and
b) and comparison of Gaussian vs. non-Gaussian setups for devices that used the Gaussian smoothing in
the clinic (c and d). Digital devices were labeled with full lines and dashed lines represent the obtained
results with analogue devices. Upper and lower RC boundaries specified by the EANM/EARL accreditation
protocols are labeled with black dashed lines. EARL RC values (black dashed lines) refers to January 2017
version as reported in the EARL website [17]
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was prepared with a good reproducibility across centers as reported in Table 2. PET
datasets were obtained by varying the number of iterations to verify signal recovery
convergence and the scan acquisition time to verify image quality stability as a function
of collected statistics. To remove the influence of PVE effect due to image smoothing,
we produced PET data without post-reconstruction smoothing when the local recon-
struction setup was adopting it.
All tested devices and reconstruction setups demonstrate a good cross-calibration
with the local dose calibrator. Deviations from BGcal = 1 were always less than 6% re-
gardless of the time per bed position (10–300 s) and the number of iterations (1 to 10).
Quantitative bias increased at low count density (as visible in Fig. 1); this behavior was
already documented and characterized in the literature [32–34]. Furthermore, the bias
observed at low count density was found to have a trend for lower levels when a list-
mode based reconstruction was used (Vereos system) while this trend was to higher
values when the reconstruction methods were based on sinograms. This behavior was
also described in the literature in conditions of low count statistics such as 90Y PET
[35], PET for ion-beam therapy monitoring [36], and low-dose 18F-FDG PET [37].
As expected, image noise increased with the number of iterative reconstruction
updates (Fig. 2a, c). In the tested conditions, digital PET systems exhibited a lower
noise level compared to analogue PET systems. This was more evident when com-
paring reconstruction setups without Gaussian filtering (Fig. 2c, d). This feature
may be potentially attributed to the synergistic improved system sensitivity and
TOF performances of digital devices compared to analogue PET. Image noise as a
function of the acquired statistics (Fig. 2b, d), also confirmed the superior noise
properties of digital PET images vs. analogue devices. In particular, we used a 15%
COV level as a reference maximum noise level for clinical evaluation as suggested
in the literature [14, 25, 27]. We found all tested clinical protocol setups character-
ized by a COV ≤ 15% for the adopted experimental setup representing a mass-
activity administration of 3.5 MBq/kg.
We reported the COV as a function of the TAP (Fig. 3). TAP values characteris-
tic of local clinical image protocols (TAPclinic, summarized in Tables 1 and 3)
Table 4 Normalized RCmean for the number for iterative updates used in clinical reconstruction
setups (and maximum RCmean values) obtained for the smallest sphere insert (diameter of 10 mm)
and a medium size insert (diameter of 17 mm) characteristic of tested PET FDG procedures.
Reconstruction protocol setups used in the clinic are labeled with (c)
PET device/recon. procedure Clinic setup,





Discovery MI M256 FWHM= 6.4 mm (c) 3 × 16 = 48 0.98 (0.48) 0.98 (0.74)
Discovery MI M256 FWHM= 0mm 3 × 16 = 48 0.92 (0.65) 0.95 (0.87)
Vereos M144 FWHM= 0mm (c) 3 × 15 = 45 0.98 (0.45) 1.0 (0.57)
Vereos M288 FWHM= 0mm (c) 2 × 10 = 20 0.89 (0.61) 0.96 (0.78)
Vision M440 FWHM= 0mm (c) 4 × 5 = 20 0.91 (0.60) 0.97 (0.84)
Discovery 690 M256 FWHM= 5mm (c) 3 × 16 = 48 0.91 (0.54) 0.97 (0.78)
Discovery 690 M256 FWHM= 0mm 3 × 16 = 48 0.89 (0.66) 0.94 (0.91)
mCT M512 FWHM= 3mm (c) 3 × 21 = 63 0.92 (0.59) 0.98 (0.76)
mCT M512 FWHM= 0mm 3 × 21 = 63 0.85 (0.64) 0.95 (0.80)
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resulted in COV close to 15% (range 9–19%). Based on this result, we can deduce
that the tested setups satisfy the requirements for clinical interpretation. Neverthe-
less, the assumed reference limit, COV = 15%, is somehow arbitrary; therefore, the
particular image pattern, signal recovery in lesions, and different clinical experience
between sites and devices would motivate possibly different optimal COV values
for clinical image evaluation. It is also worth remarking that COV alone does not
represent the most significant metric for comparing image quality across devices
and protocol setups, since this parameter depends not only on overall device
performance and reconstruction parameters but also on the injected specific mass-
activity and the adopted scan time duration per bed position. For this reason, we
adopted the TAPCOV-15 as a term of comparison between different technologies.
The COV obtained at clinical TAP, however, was reported to characterize the dif-
ferent clinical protocols.
Our results confirm lower TAPclinic (range 3–4 min·MBq/kg) and are currently used
with digital PET devices compared to the tested analogue PET (TAPclinic = 5.25 min ×
MBq/kg or higher). On average, a 40% TAP reduction was reported in clinical configu-
rations in favor of digital PET.
When considering TAPCOV-15, if we exclude the mCT device (thus considering it
an outlier), analogue systems are represented by the only value of 3.7 min ×MBq/
Fig. 5 Transaxial views of the image quality of phantom images obtained with clinical setups
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kg used with the Discovery 690 (M256, Gaussian smoothing FWHM= 5mm). Ac-
cordingly, the average TAPCOV-15 obtained from digital PET systems (2.84 min ×
MBq/kg, range 1.4–4.5 min ×MBq/kg) is 23% lower than the TAPCOV-15 obtained
for the analogue Discovery 690.
We should also consider that the clinical setup adopted for the Discovery 690 in-
cludes a Gaussian smoothing (FWHM= 5mm) that helps reducing TAPCOV-15 values,
while, excluding the Discovery MI (M256, FWHM= 6.4 mm) setup, all other clinical
setups adopted in digital devices did not used Gaussian smoothing.
The differential improvement of new systems is even more evident when comparing
similar setups without the use of Gaussian smoothing. For instance, according to data
reported in Table 3, comparing the Discovery 690 with the Discovery-MI that used the
same image matrix (256 × 256) and iterations × subsets (3 × 16), the TAPCOV-15was
13.2 min ×MBq/kg and 3.9 min ×MBq/kg, respectively, corresponding to a 70% TAP-
COV-15 reduction in favor of the digital PET system. This translates to a lower mass-
activity administration and/or shorter scan times at matched image noise levels.
Accordingly, patient comfort (at matched image quality) can be improved and/or dose
exposure reduction can be achieved as discussed in the recent clinic works of Behr
et al. [38] and Van Sluis et al. [39].
RCmax and RCA50 (Fig. 4) higher than the present reference EANM/EARL levels were
commonly obtained in all clinical protocol setups tested. These values are typical of
PET reconstructions adopting TOF and PSF corrections [26].
The EARL proposed a target range of RCs to promote inter-device and inter-center
comparison of quantitative PET data. This is not always the purpose in local clinical
setups. Most often, the local clinical demand favor image contrast and spatial resolution
(reduced PVE) with resulting higher RCs values compared to the proposed EARL
range.
Lower RC levels were observed for the clinical setups in the Discovery MI, as a con-
sequence of the 6.4-mm Gaussian filter applied and for the Vereos system adopting the
144 × 144 matrix size which results in large voxels with consequent large PVE in small
structures. By definition, RCmax and RCA50 depend on the voxel with the maximum
value and are intrinsically sensitive to the image noise level. Accordingly, we observed
they increased with the number of iterations and decreased image statistics (Add-
itional file 1: Figures S3 and S4) especially for reconstruction protocols without image
smoothing. For the tested conditions, an important deviation of RCmax and RCA50
(higher RCs) can arise for scan times shorter than 60 s.
A normalized RCmean was used to test the signal recovery convergence as a func-
tion of the number of iterative updates. Across the tested clinic protocol setups, a
reasonable level of convergence (RCmean,N ≥ 89%) was obtained even for the smal-
lest spherical insert (10 mm in diameter). In particular, there are two systems exhi-
biting a faster convergence rate: the Biograph Vision and the Vereos, the first
probably due to the best TOF timing resolution (214 ps), and the latter probably
thanks to the favorable convergence properties of the blob-based OSEM iterative
reconstruction algorithm [40], having a TOF time resolution of 316 ps, an inter-
mediate value compared to the Siemens and the GE digital systems. We also ob-
served faster convergence for reconstruction setups adopting Gaussian smoothing
compared to reconstruction without smoothing. This behavior can be attributed to
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the peculiarity of image smoothing in reducing high spatial frequency (typical of
small structures) that are known to require more iterations to converge when com-
pared to lower spatial frequency (characterizing large structures) that is also the
reasons why this behavior is more evident for the spheres of smaller size.
Compared to the tested OSEM iterative reconstruction setups, the Q.Clear implemented
in the Discovery-MI PET/CT showed (at least) comparable performances. This reconstruc-
tion method indeed, guarantees a good level of signal recovery coupled with favorable noise
properties. It was not our goal in this work to systematically characterize the Q.Clear algo-
rithm, something which has been discussed elsewhere in the literature [24, 40].
Concerning the signal recovery performances, we did not observe major differences
between conventional PMT-based PET and recently introduced digital PET devices (all
reconstructions used PSF correction). The work of Kaalep et al. [26] pointed out the
convenience of adopting a new range of signal recovery coefficients that thanks to the
inclusion of PSF all PET devices can achieve. Kaalep et al. tested analogue PET devices,
but in light of the results presented in our work, their methodology and results are in
principle transferable to recently available digital PET.
We also noticed that, thanks to the improved system sensitivity and TOF capabilities,
clinical protocols implemented in digital PET devices tend to avoid image smoothing.
This fact coupled with the use of a relatively small voxel size (ex. 1.65 × 1.65 × 2mm3
for the tested Biograph Vision device) can help reducing partial volume effects. Conse-
quently, based on our results, we expect at a matched activity distribution present
across the device FOV, and at a matched acquisition time duration, the digital PET po-
tentially provide higher contrast-to-noise ratios, thus possibly improving lesions detec-
tion and quantitative accuracy.
Limitations
Despite the limited number of tested PET devices, digital PET (n = 3) and analogue
PET (n = 2), we found reasonable indications on the potential of operating digital de-
vices at lower TAP compared to conventional analogue ones at matched image quality.
Furthermore, matched image quality was achievable (for instance COV = 15%, as used
in our study) in digital PET without applying additional image smoothing and/or using
smaller voxel size with potential benefit in reducing PVE.
Conclusion
This work is the result of the collaboration of different PET centers in Switzerland and
was, to the best of our knowledge, the first study comparing the image quality obtained
for clinical whole-body oncologic 18F-FDG PET protocols using the three recently in-
troduced digital PET devices. We further extended the comparison to two analogue
PET devices equipped with conventional PMTs. The methodology, based on a well-
characterized NEMA/IEC NU2 phantom, highlighted the improved signal-to-noise ra-
tios achievable with the new digital PET devices compared to conventional ones. With
appropriate protocol optimization in terms of acquisition and reconstruction parame-
ters, we found that sensible improvements in patient comfort (reduced scan time for
the same matched image quality) and/or dose exposure (reduced administered activity)
are achievable.
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Supplementary information accompanies this paper at https://doi.org/10.1186/s40658-019-0269-4.
Additional file 1: Figure S1. Signal recovery convergence in spheres of different size for iterative reconstruction
setups without Gaussian smoothing. Reconstruction setups implemented in digital devices were labeled with full
lines, dashed lines denotes reconstruction setups implemented in analogue devices. Figure S2 Signal recovery
convergence in spheres of different size. Comparison of Gaussian vs. non-Gaussian setups for devices that used the
Gaussian smoothing in clinic. Reconstruction setups implemented in digital devices were labeled with full lines,
dashed lines denotes reconstruction setups implemented in analogue devices. Figure S3. RCmax as function of
acquisition time for the different spheres, for iterative reconstruction setups without Gaussian smoothing Recon-
struction setups implemented in digital devices were labeled with full lines, dashed lines denotes reconstruction
setups implemented in analogue devices. Upper and lower RC boundaries specified by the EANM/EARL accredit-
ation protocols are labelled with black dashed lines. EARL RC values (black dashed lines) refers to January 2017
version as reported in the EARL website [17]. Figure S4. RCmax as function of acquisition time for the different spheres.
Comparison of Gaussian vs. non-Gaussian setups for devices that used the Gaussian smoothing in clinic. Reconstruction
setups implemented in digital devices were labeled with full lines, dashed lines denotes reconstruction setups imple-
mented in analogue devices. Upper and lower RC boundaries specified by the EANM/EARL accreditation protocols are
labelled with black dashed lines. EARL RC values (black dashed lines) refers to January 2017 version as reported in the
EARL website [17].
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